Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Cost-effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients.

Hallinen T, Soini EJ, Linna M, Saarni SI.

Springerplus. 2016 Aug 17;5(1):1354. doi: 10.1186/s40064-016-3024-5. eCollection 2016.

2.

Cost-Effectiveness of First-Line Disease-Modifying Therapies (Dmts) For Relapsing-Remitting Ms (Rrms).

Soini EJ, Joutseno J, Sumelahti M.

Value Health. 2015 Nov;18(7):A756. doi: 10.1016/j.jval.2015.09.2459. Epub 2015 Oct 20. No abstract available.

3.

Cost-Effectiveness of Ustekinumab In The Treatment of Psoriasis In Finland.

Väätäinen S, Soini EJ, Valgardsson VS, Mälkönen T.

Value Health. 2015 Nov;18(7):A670. doi: 10.1016/j.jval.2015.09.2449. Epub 2015 Oct 20. No abstract available.

4.

Health Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine In Finnish Home Care Customers ≥50 Years With Underlying Chronic Medical Conditions.

Mankinen PT, Soini EJ, Laine J, Linna M, Åhman H, Martikainen J.

Value Health. 2015 Nov;18(7):A579. doi: 10.1016/j.jval.2015.09.1932. Epub 2015 Oct 20. No abstract available.

5.

Cost-utility of first-line actinic keratosis treatments in Finland.

Soini EJ, Hallinen T, Sokka AL, Saarinen K.

Adv Ther. 2015 May;32(5):455-76. doi: 10.1007/s12325-015-0211-7. Epub 2015 May 26.

6.

Cost-Utility of Vortioxetine in the Treatment of Major Depressive Disorder: Comparison with Agomelatine, Bupropion, Sertraline and Venlafaxine in the Finnish Setting.

Soini EJ, Hallinen T, Brignone M, Despiégel N, Aalto-Setälä M, Danchenko N, Kolasa K.

Value Health. 2014 Nov;17(7):A459. doi: 10.1016/j.jval.2014.08.1267. Epub 2014 Oct 26. No abstract available.

7.

Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults ≥50 years with underlying chronic medical conditions.

Martikainen JA, Soini EJ, Laine J, Ahman H, Postila V, Klemets P.

J Eval Clin Pract. 2014 Aug;20(4):333-41. doi: 10.1111/jep.12131. Epub 2014 May 10.

PMID:
24813690
8.

Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data.

Hallinen T, Soini EJ, Asseburg C, Kuosmanen P, Laakkonen A.

BMJ Open. 2014 Feb 27;4(2):e004071. doi: 10.1136/bmjopen-2013-004071.

9.

Administration costs of intravenous biologic drugs for rheumatoid arthritis.

Soini EJ, Leussu M, Hallinen T.

Springerplus. 2013 Oct 17;2:531. doi: 10.1186/2193-1801-2-531. eCollection 2013.

10.

Efficacy of a multicomponent support programme for the caregivers of disabled persons: a randomised controlled study.

Ryynänen OP, Nousiainen P, Soini EJ, Tuominen S.

Z Gerontol Geriatr. 2013 Jul;46(5):449-55. doi: 10.1007/s00391-012-0360-0.

PMID:
23743879
11.

Bayesian predictors of very poor health related quality of life and mortality in patients with COPD.

Ryynänen OP, Soini EJ, Lindqvist A, Kilpeläinen M, Laitinen T.

BMC Med Inform Decis Mak. 2013 Mar 7;13:34. doi: 10.1186/1472-6947-13-34.

12.

Differential use of extended and immediate release quetiapine: a retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders.

Hallinen T, Soini EJ, Granström O, Ovaskainen Y, Leinonen E, Koponen HJ, Hänninen K.

BMJ Open. 2012 Jul 2;2(4). pii: e000915. doi: 10.1136/bmjopen-2012-000915. Print 2012.

13.

The association between anxiety and the degree of illness in mild obstructive sleep apnoea.

Lehto SM, Sahlman J, Soini EJ, Gylling H, Vanninen E, Seppä J, Viinamäki H, Tuomilehto H.

Clin Respir J. 2013 Apr;7(2):197-203.

PMID:
22686135
14.

Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.

Soini EJ, Martikainen JA, Vihervaara V, Mustonen K, Nousiainen T.

Clin Ther. 2012 Apr;34(4):915-925.e2. doi: 10.1016/j.clinthera.2012.02.019. Epub 2012 Mar 27.

PMID:
22459623
15.

Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.

Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ.

J Med Econ. 2012;15(2):340-51. doi: 10.3111/13696998.2011.649327. Epub 2012 Jan 6.

PMID:
22168785
16.

Health economic consequences of reducing salt intake and replacing saturated fat with polyunsaturated fat in the adult Finnish population: estimates based on the FINRISK and FINDIET studies.

Martikainen JA, Soini EJ, Laaksonen DE, Niskanen L.

Eur J Clin Nutr. 2011 Oct;65(10):1148-55. doi: 10.1038/ejcn.2011.78. Epub 2011 May 18.

17.

Cost-utility and expected value of perfect information related to trabectedin in the treatment of metastatic soft-tissue sarcoma: the publicly funded comments explored.

Soini EJ.

Ann Oncol. 2011 Jun;22(6):1465-6. doi: 10.1093/annonc/mdr268. Epub 2011 May 9. No abstract available.

PMID:
21555363
18.

Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up.

Soini EJ, Martikainen JA, Nousiainen T.

Ann Oncol. 2011 May;22(5):1189-97. doi: 10.1093/annonc/mdq582. Epub 2010 Dec 6.

19.

Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information.

Soini EJ, García San Andrés B, Joensuu T.

Ann Oncol. 2011 Jan;22(1):215-23. doi: 10.1093/annonc/mdq339. Epub 2010 Jul 13.

20.

Risk factors for persistent frequent use of the primary health care services among frequent attenders: a Bayesian approach.

Koskela TH, Ryynanen OP, Soini EJ.

Scand J Prim Health Care. 2010 Mar;28(1):55-61. doi: 10.3109/02813431003690596.

Supplemental Content

Loading ...
Support Center